Pfizer expects to have safety and efficacy data for its COVID-19 vaccine in children in late September

Pfizer Inc. expects to share data about the safety and efficacy of the COVID-19 vaccine it developed with BioNTech SE for children between the ages of 5 and 11 years old by the end of September, with plans to file for emergency authorization in the U.S. in early October, according to remarks made by company executives on Tuesday. Clinical data for children 6 months old to 5 years old is expected shortly after. "All of that depends on having a positive outcome on the data, right? I'm assuming that in terms of all the dates I'm giving you," Pfizer CFO Frank D'Amelio told investors Tuesday at the Morgan Stanley Global Healthcare Conference, according to a FactSet transcript of the presentation. The BioNTech/Pfizer vaccine is currently authorized for teens between the ages of 12 and 15 years old and is fully approved for those 16 years old and older. Pfizer's stock is up 21.4% this year, while the S&P 500 has gained 18.9%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Pfizer expects to have safety and efficacy data for its COVID-19 vaccine in children in late September
Pfizer Inc. expects to share data about the safety and efficacy of the COVID-19 vaccine it developed with BioNTech SE for children between the ages of 5 and 11 years old by the end of September, with plans to file for emergency authorization in the U.S. in early October, according to remarks made by company executives on Tuesday. Clinical data for children 6 months old to 5 years old is expected shortly after. "All of that depends on having a positive outcome on the data, right? I'm assuming that in terms of all the dates I'm giving you," Pfizer CFO Frank D'Amelio told investors Tuesday at the Morgan Stanley Global Healthcare Conference, according to a FactSet transcript of the presentation. The BioNTech/Pfizer vaccine is currently authorized for teens between the ages of 12 and 15 years old and is fully approved for those 16 years old and older. Pfizer's stock is up 21.4% this year, while the S&P 500 has gained 18.9%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.